Company news
Xspray Pharma Ab (OMXSTO:XSPRAY) news
Xspray Pharma Ab news releases on 6ix. Latest, Apr 23, 2026: Xspray’s rights issue oversubscribed – over-allotment issue fully utilized
Press releases & updates
Xspray’s rights issue oversubscribed – over-allotment issue fully utilized
April 23, 2026
Xspray publishes disclosure document regarding rights issue
March 31, 2026
Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased
March 26, 2026
Xspray Pharma publishes its Annual Report 2025
March 26, 2026
Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue
March 24, 2026
Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026
March 11, 2026
Xspray Pharma re-submits its FDA application for Dasynoc
February 26, 2026
Xspray Pharma appoints Blake Leitch as CEO – Per Andersson continues as Chief Scientific Officer (CSO)
February 26, 2026
Xspray Pharma: FDA accepts New Drug Application for XS003 (nilotinib) for the treatment of CML - PDUFA date set for June 18, 2026
October 21, 2025
Xspray Pharma: FDA accepts New Drug Application for XS003 (nilotinib) for the treatment of CML – PDUFA date set for June 18, 2026
October 21, 2025
Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform
August 19, 2025
Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa’s Net Proceeds
August 12, 2025